Repurpose drugs for new indications
Repositioning existing, approved drugs for additional indications circumvents some of the most expensive aspects of the drug discovery process, thanks to previously established safety and pharmacokinetic profiles. The use of proteomics is greatly expanding our understanding of disease biology and drug mode of action, with great potential to identify commonalities and shared pathways among different diseases and thereby guide repurposing efforts.
Selected webinars
Hear what thought leaders in the biomedical and pharmaceutical industries have to say about the rapidly accelerating role of proteomics in understanding disease biology and guiding the next generation of more effective therapies targeted to the right patients.
How proteomics can help redefine how we understand disease
Genomics has provided a wealth of data to better understand disease biology and has enabled significant advances in the development of novel therapies for some diseases, most notably in the oncology field. It is clear, however, that more comprehensive investigations are required to accelerate progress across a broad spectrum of disease areas. Proteomics adds a vital complementary approach to provide a much needed extra layer of resolution to genetic data.
Protein biomarkers help to unravel the complex interplay between environment and phenotype and may help us move towards a more pathway-based understanding of human disease. This will not only help guide the development of new therapies but may also provide an invaluable resource for repurposing existing drugs through the identification of common pathways.
Selected publications
These publications showcase how Olink’s PEA technology aids drug repurposing by identifying biomarkers and protein profiles. Studies include heart failure (EMPEROR trials), COVID-19 (tocilizumab response), rheumatoid arthritis (anti-TNF therapy), and neurological diseases, revealing common pathways to guide repurposing.
A flexible platform that accelerates your research
Olink’s scalable technology provides optimized solutions for every stage of the biomarker workflow, from high-throughput discovery through validation and clinical utility.
Get help choosing. Talk to a Specialist.
Olink Explore HT
Measure 5,400+ proteins with proven specificity to gain an understanding of disease at the protein level.
Proteins
5,400+ With proven specificity
Sample
2 µL Plasma, serum & more
Olink Flex
Run individually tailored studies by combining up to 21 biomarkers from our extensive library with minimal sample volume.
Proteins
~200 Pre-validated assays
Sample
1 µL Plasma, serum & more
Olink Target 96
Target specific disease areas or key biological processes with multiplex immunoassay panels.
Proteins
1,100+ On 15 targeted panels
Sample
1 µL Plasma, serum & more
Olink Target 48
Extensively validated and carefully selected biomarkers for a comprehensive view of cytokine signaling and inflammatory processes.
Proteins
89 On 2 panels
Sample
1 µL Plasma, serum & more